Sitagliptin-Plus Sandoz Indications/Uses

For adult patients with type 2 diabetes mellitus: Sitagliptin-Plus Sandoz is indicated as one of the choices of drugs for initial therapy in patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control.
Sitagliptin-Plus Sandoz is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus inadequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin.
Sitagliptin-Plus Sandoz is indicated as part of triple combination therapy with a sulphonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: metformin, sitagliptin or a sulphonylurea.
Sitagliptin-Plus Sandoz is indicated as part of triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: metformin, sitagliptin or a PPARγ agonist.
Sitagliptin-Plus Sandoz is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with insulin.